Unibest

Pharmaceutical intermediates

Adagrasib Intermediates

13 pharmaceutical intermediates for Adagrasib. Indication: Colorectal Cancer; Non-Small Cell Lung Cancer.

About Adagrasib

Originator
Mirati Therapeutics Inc; Array Biopharma
Indication
Colorectal Cancer; Non-Small Cell Lung Cancer
Approved Date
12/12/2022
NCE Patent
12/12/2027
DS/DP
05/17/2037

Available intermediates

13 intermediates currently listed for Adagrasib. Request specifications, documentation or a quotation for any item below.

Adagrasib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(S)-2-(Piperazin-2-yl)acetonitrile dihydrochloride2158301-19-8//
sodium 2-fluoroacrylate74893-46-2//
8-chloronaphthalen-1-amine59107-51-6//
methyl 1-(8-chloronaphthalen-1-yl)-3-oxopiperidine-4-carboxylate2898538-56-0//
7-(8-chloronaphthalen-1-yl)-2-mercapto-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol2898538-57-1//
1-Bromo-8-chloronaphthalene20816-79-9//
tert-butyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate916420-27-4//
7-Benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyriMidine1059735-34-0//
Ethyl N-benzyl-3-oxo-4-piperidine-carboxylate hydrochloride52763-21-0//
7-(8-chloronaphthalen-1-yl)-2-(isopropylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol2898538-61-7//
(S)-7-(8-chloronaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol2408250-15-5//
2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile2206737-06-4//
2-FLUOROACRYLIC ACID430-99-9//

Building toward Adagrasib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

我们能如何帮助您?

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →